BTIG Research Has Lowered Expectations for MDxHealth (NASDAQ:MDXH) Stock Price

MDxHealth (NASDAQ:MDXH) had its price target decreased by BTIG Research from $4.00 to $2.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 177.78% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Lake Street Capital set a $3.00 price objective on MDxHealth and gave the stock a “buy” rating in a research report on Friday, August 14th. William Blair cut MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. TD Cowen reaffirmed a “buy” rating and set a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Finally, Wall Street Zen raised MDxHealth to a “sell” rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.17.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $0.72 on Friday. The stock has a market cap of $35.64 million, a price-to-earnings ratio of -1.00 and a beta of 1.42. MDxHealth has a 1 year low of $0.40 and a 1 year high of $5.33. The business has a fifty day moving average of $0.49 and a 200-day moving average of $1.69.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $27.21 million for the quarter, compared to analysts’ expectations of $26.14 million. On average, equities research analysts predict that MDxHealth will post -0.49 EPS for the current year.

Hedge Funds Weigh In On MDxHealth

Several institutional investors have recently added to or reduced their stakes in MDXH. Intesa Sanpaolo Wealth Management acquired a new position in MDxHealth in the fourth quarter worth $36,000. Lido Advisors LLC bought a new position in MDxHealth in the third quarter valued at approximately $48,000. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth during the third quarter worth $53,000. Squarepoint Ops LLC bought a new stake in shares of MDxHealth in the 4th quarter valued at about $51,000. Finally, Bank of America Corp DE raised its holdings in MDxHealth by 5,164.0% in the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares during the period.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.